Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Single-cell ribosome profiling to monitor the translational landscape of tumor-initiating cells

Project description

Protein synthesis regulation in tumour-initiating cells

Tumours are complex ecosystems containing rare cells capable of initiating and sustaining growth and progression. These tumour-initiating cells, often likened to cancer stem cells, are thought to drive therapy resistance and disease relapse. A defining feature of these cells is unusually low protein synthesis activity. However, how this translational control shapes their behaviour remains poorly understood. The ERC-funded RIBOSCOPE project develops innovative tools to map protein synthesis at single-cell resolution within tumours in living animals. Researchers will focus on profiling ribosomes, the machinery responsible for protein synthesis. By identifying the translational programmes in tumour-initiating cells that drive cancer progression and resistance, the project will uncover novel therapeutic targets specifically aimed at eliminating these critical cells.

Objective

Temporal control of gene expression is critical for cancer cells. However, while transcriptional control has been extensively studied in cancer, it has become evident that translational control is a major determinant of protein abundance and cellular function. Therefore, protein synthesis pathways have immense, hitherto untapped potential to understand tumorigenesis and may provide novel entry points for cancer therapies.
Tumors are heterogeneous tissues, where a small subset of tumor-initiating cells plays a key role in cancer progression and therapy resistance. Tumor-initiating cells exhibit low protein synthesis rates, a hallmark of stemness, yet how translational control impacts their function remains enigmatic.
Here, we will develop an in vivo strategy to comprehensively monitor the translational landscape of tumor-initiating cells at single-cell resolution. Leveraging our recently established in vivo single-cell ribosome profiling strategy, ultrasound-guided in utero lentiviral microinjections and an elegant mouse model of cancer, we plan to track and perturb tumor-initiating cells in their native environment. First, we will develop and validate a method to annotate the in vivo single-cell translational efficiency landscape of tumor-initiating cells. Second, focusing on translationally altered genes in tumor-initiating cells, we will identify translational programs driving tumor progression and therapy resistance in vivo. Third, we will molecularly characterize key translational efficiency genes and integrate spatial transcriptomics to map tumor-initiating cell behavior.
Collectively, the unique combination of advanced tools will offer unprecedented and systematic insights into the translational landscape of tumor-initiating cells, identify novel translationally regulated genes driving cancer progression and therapy resistance and lay the foundation for developing novel therapies that specifically target tumor-initiating cells in cancer patients.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-COG

See all projects funded under this call

Host institution

UNIVERSITAT ZURICH
Net EU contribution
€ 2 992 158,00
Address
RAMISTRASSE 71
8006 Zurich
Switzerland
Region
Schweiz/Suisse/Svizzera Zürich Zürich
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 992 158,00

Beneficiaries (1)